Despite decades of focused research, the field has yet to develop a prophylactic vaccine. In the 25 RV144 vaccine trial, non-neutralizing antibody responses were identified as a correlate for 26 prevention of HIV acquisition. However, factors that predict the development of such antibodies 27 are not fully elucidated. We sought to define the contribution of circulating T follicular helper 28 (cTfh) cell subsets to the development of non-neutralizing antibodies in HIV-1 clade C infection. 29
Introduction 58
A safe and effective prophylactic vaccine remains the most efficient way of ending the 59 HIV/AIDS epidemic which affects over 36 million people worldwide (1). Although studies in 60 non-human primate and animal models have demonstrated the efficacy of anti-HIV broadly 61 neutralizing antibodies (bNAbs) in preventing HIV infection, human vaccine trials to date have 62 been largely unsuccessful in inducing such responses (2) (3) (4) . Thus, an improved understanding of 63 the mechanisms that underlie the development of functional and durable anti-HIV antibody 64 responses in the context of a natural infection will be essential for optimal vaccine design efforts 65 (5) . Moreover, with the quality of immune responses in early acute HIV infection predicting 66 disease outcome (6, 7), early acute HIV infection is a useful model to identify early correlates of 67 HIV-1 control. 68 69 T follicular helper (Tfh) cells, a lineage of CD4 + T cells that express the chemokine receptor 70 CXCR5, are specialized for B cell help and the development of antibody responses (8, 9) . Tfh-B 71 cell interactions in the B cell follicles promote germinal center (GC) formation, B cell 72 differentiation, B cell survival, antibody affinity maturation and class switch recombination (8, 73 10) . The circulating memory counterparts of bona fide germinal center Tfh cells have been 74 recently described (11, 12) . These cells display either an activated or quiescent phenotype based 75 on the expression of PD-1 and ICOS or CCR7 receptors and can be further divided into subsets 76 based on the expression of CXCR3 and CCR6 receptors (12, 13) . The subsets; Tfh1, Tfh2, Tfh17 77 and Tfh1-17, were named due to their similarities to other T helper cell lineages. Tfh1 cells 78 express CXCR3 like Th1 cells, Tfh2 cells produce IL-4 like Th2 cells, Tfh17 cells express CCR6 79 similar to Th17 cells and Tfh1-17 cells have functional properties that are similar to both Th1 80 and Th17 cells (12) (13) (14) . 81 82 From the RV144 vaccine trial, which had a modest efficacy in preventing HIV acquisition, we 83 learned that non-neutralizing antibodies (nnAbs) could protect against HIV acquisition (15) . 84
Consistent with this observation, a recent study exploring the efficacy of nnAbs for blocking 85 virus entry, showed that anti-Env nnAbs could modulate the transmission of simian HIV (SHIV) 86 in macaques and reduce the number of transmitted/founder viruses establishing infection in the 87 animals (16). Moreover, a humanized mouse model of HIV infection, reported near-complete 88 clearance of adoptively transferred infected cells within 5 hours of nnAbs treatment (17) further 89 5 demonstrating the potential for nnAbs in preventing HIV infection. Specific Tfh subsets have 90 been shown to help the induction of various antibody functions. For instance, a recent study 91 correlated the frequencies of CXCR3 -cTfh; which includes both Tfh2 and Tfh17 subsets, with 92 the development of bNAbs against HIV infection (18), suggesting a potential role of these 93 subsets as correlates for the induction of bNAbs in infection and possibly by vaccines. It is thus 94 important to define specific Tfh subsets that contribute to nnAbs development in the context of 95 natural HIV infection. 96
97
Here we investigated if the induction of cTfh responses during acute HIV infection contribute to 98 initial HIV control and promote the development of anti-HIV nnAbs. We examined the role of 99
HIV-specific cTfh cell subsets during acute HIV infection using HLA class II tetramers and 100 multiparametric flow cytometry. HIV-specific antibody responses were further measured using a 101 customized multivariate Luminex assay. Our results showed that acute HIV infection induces 102 significant expansion of HIV-specific memory Tfh1 cells (p=0.02), which correlated with lower 103 set point viral loads. Moreover, the frequencies of Tfh1 cells during early infection were 104 predictive of p24-specific IgG titers. These data suggest that circulating Tfh1 cells play a role in 105 controlling viral replication during primary HIV infection by enhancing robust anti-HIV 106 antibody production, which is desirable for a prospective HIV vaccine. 107 108
Results

109
Circulating CXCR5 + cells in healthy donors have a predominantly central memory 110 phenotype. Recent studies have focused on characterizing circulating CXCR5 + CD4 + T cells 111 (cTfh) because of their similarities with germinal center Tfh cells and their potential role in the 112 6 development of bNAbs (18, 19) . The difficulty associated with obtaining bona fide Tfh from 113 lymphoid tissues has also stirred the interest in studying cTfh as surrogates. Although the 114 phenotype of cTfh has not been clearly defined, the consensus is that they represent circulating 115 memory Tfh (13). To determine how HIV infection perturbs global frequencies and phenotypes 116 of peripheral Tfh we began by establishing baseline characteristics of this cell population in our 117 study cohort who are predominantly of the Zulu/Xhosa ethnicity. We used CCR7 and CD45RA, 118 well established memory markers to define four memory subsets. Specifically, we defined naïve 119 (N) T cells by gating on CCR7 + and CD45RA + , central memory (CM) by CCR7 + CD45RA -, 120 effector memory (EM) by CCR7 -CD45RA -, and terminally differentiated effector memory 121 (TEMRA) by CCR7 -CD45RA + (20) ( Figure 1A ). Phenotypic analysis of total CD4 + T cells from 122 12 HIV negative donors revealed that 34.0% (29.1-43.2) were naïve, 21.8% (19.1-28.0) were 123 CM, 33.7% (30.4-44.4) were EM and 2.8% (2.1-3.3) were TEMRA ( Figure 1B ). Next, we 124 measured the frequency of cTfh (CXCR5 + CD4 + ) cells and found that they comprised 12% (10.1-125 7 ( Figure 2A ), HIV infection did not alter the overall frequencies of total circulating memory Tfh. 136
However, memory subset analysis revealed an increase in naïve Tfh (p=0.004) and TEMRA Tfh 137 (p=0.02), whereas CM Tfh (p=0.13) and EM Tfh (p=0.16) remained unchanged ( Figure 2B ). 138 139 Next, we used CXCR3 and CCR6 chemokine receptor markers to characterize cTfh subsets in an 140 effort to identify which subset most influences the generation of anti-HIV antibodies during 141 acute HIV infection. CXCR3 and CCR6 chemokine receptor markers have been previously used 142 to identify several functional subsets that exhibit distinct B cell helper functions namely: Tfh1 143 (CXCR3 + CCR6 -), Tfh2 (CXCR3 -CCR6 -), Tfh1-17 (CXCR3 + CCR6 + ) and Tfh17 (CXCR3 -144 CCR6 + ) (13). A representative flow plot, as seen in Figure 2C hypothesized that Tfh1 responses impact SPVL by driving the production of HIV-specific IgG 165 antibodies. We measured plasma gp41, gp120, p17 and p24-specific IgG antibody titers at 12 166 months after infection for 10 study participants based on sample availability. Correlation analysis 167 of IgG titers with SPVL revealed a negative correlation between SPVL and p24 IgG (p=0.007 168 r=-0.81) ( Figure 4A ) or gp41 IgG (p=0.009, r=-0.80) ( Figure 4B ) and no significant correlations 169 between SPVL and p17 IgG (p=0.09, r=-0.58) ( Figure 4C ) or gp120 IgG titers (p=0.20, r=-0.44) 170 ( Figure 4D ). We also examined the correlation of SPVL to the titers of p24 IgG isotypes; IgG1, 171
IgG2, IgG3 and IgG4 and found no significant correlations between the p24 IgG isotypes and 172 SPVL ( Figure 4E and data not shown). 173 174 Lastly, we interrogated the relationship between Tfh1 frequencies and antibody titers. We found 175 that Tfh1 frequencies during early infection (5.0-8.0 weeks) were directly correlated to the 176 plasma titers of p24 IgG (p=0.003, r=0.85), p17 IgG (p=0.01, r=0.77), gp41 IgG (p=0.05, r=0.65) 177 and p24 IgG1 (p=0.04, r=0.66) that were detected at 1 year post-infection ( Figures 4F, 4G , 4H 178 and 4I). There was however, no association between gp120 titers and Tfh1 frequencies ( previously showed that most of the HIV-specific CD4 + T cells in chronic clade C infection target 191 the HIV Gag protein (26). Here we found no significant differences in Gag, Nef and Env 192 responses ( Figure 5B ). Further interrogation of the cytokine profile of cTfh cells revealed that 193 unlike SEB-specific cells which abundantly secreted TNF-α and IFN-γ ( Figure 5C ), HIV-194 specific cTfh were biased towards the secretion of Tfh functional cytokines: IL-21 and IL-4, with 195 lower proportions of cTfh cells secreting TNF-α and IFN-γ ( Figure 5D ). Comparative analysis 196 with non cTfh cells revealed that HIV-specific cTfh cells (blue) secreted more IL-21 ( Figure 5E had strong a response to the Gag C41 epitope restricted by DRB1*11:01 HLA haplotype, dual 204 tetramer positive cells were detected within CD4 + T cells ( Figure 6A ). An overlay of these 205 double tetramer CD4 + population onto CXCR5 + CXCR3 + CD4 + cTfh showed that HIV-specific 206 cTfh were predominantly CXCR3 + (Tfh1 and Tfh1-17) cells and were detectable at 12, 14, 16 207 and 20 weeks post-infection ( Figure 6B ). Persistent HIV-specific cTfh cells during HIV-1 208 infection, was observed in another acute patient (patient 2) at 6 weeks and 138 weeks post 209 infection ( Figure 6C ). Five additional patients expressing either the DRB1*11:01 (n=4) or the 210 DRB1*13:01 (n=1) HLA haplotypes had detectable HIV-specific cTfh responses in chronic 211 infection (>2 years of infection). Combined data for the 7 patients tested ( Table 2) showed 212 significantly higher frequencies of CXCR3 + (Tfh1 and Tfh1-17) tetramer-specific cells compared 213 to Tfh2 and Tfh17 (p=0.0007) ( Figure 6D ). Together, these results demonstrate that HIV-specific 214 cTfh cells persist during HIV infection. The differential induction of cTfh subsets has been described in the context of other infectious 238 diseases. Consistent with our data, the early induction of circulating CXCR3 + cTfh, which 239 comprises Tfh1 and Tfh1-17 subsets, correlated with the emergence of protective responses to 240 the Influenza vaccine (31). In a subsequent study, they further demonstrated that CXCR3 + Tfh 241 cells promote the development of high avidity antibody responses to the H1N1 vaccine (32). The 242 aforementioned studies and our data suggest that Tfh1 cells might play an important helper role 243 in the production of efficacious antiviral nnAbs. However, since studies using in vitro Tfh and B 244 cell co-culture assays, have shown that CXCR3 + Tfh cells are effective in providing help to 245 memory B cells but deficient at offering naïve B cell help (11, 18), more mechanistic work using 246 animal models will be critical to delineating the intricacies of circulating Tfh1 cell helper 247 capacity and providing clarity on the functional ability of Tfh1 subsets. 248 12 From our results, we also observed an expansion of the Tfh2 subsets during acute HIV-1 250 infection compared to the controls. The CXCR3subset which comprises Tfh2 and Tfh17 subsets 251 has been described as having superior helper capacity in-vitro (11, 18) and the frequencies 252 during acute HIV-1 infection was predictive of the ability to develop bNAbs in one study (18) . 253
However, another study did not see any relationship between this subset and the ability to 254 develop bNAbs (22) . Although, we sought to determine the relationship between the Tfh2 subset 255 and bNAbs development in our study, only one study participant developed bNAbs thus, we 256 were unable to make any conclusions. infection (35, 36) . In the initial study, a faster onset and magnitude of antibody-dependent cell-271 mediated virus inhibition mediated by Env-specific antibodies, was observed in immunized 272 13 animals compared to controls (35, 36) . Human studies of cTfh cells comparing the effector 273 profile of cTfh cells having different HIV-protein specificity, showed that Env-specific cTfh 274 cells were superior at inducing class switching to IgG while Gag-specific cTfh cells were better 275 at inducing B cell proliferation and maturation (37). These assays were conducted in-vitro but 276 the micro-anatomy of immune responses in-vivo might encourage interactions between cells of 277 different specificities. Additionally, studies have alluded to some degree of promiscuity in Tfh 278 cell help to B cells in the GCs. It has been shown that the Tfh response is polyclonal (38), also 279 the egression of Tfh cells from their initial colonized GCs and migration into other GCs have 280 been documented (38, 39) . These kinds of results argue for a less rigid Tfh help and highlight the 281 dynamism of Tfh cell-B cell interactions which are the subject of many studies. 282
283
As previously mentioned, our tetramer staining results give a strong indication that cTfh cells 284 persist in circulation well into chronic HIV infection. Although there were significantly higher 285 frequencies of Tfh2 cells compared to Tfh1 cells during acute HIV, there was a higher proportion 286 of tetramer specific Tfh1 cells. The tetramers we tested were directed at the Gag C41 epitope and 287 one possibility is that Tfh2 cells may be targeting a different epitope other than the Gag C41 288 epitope which we interrogated. We however, consider the expansion of the Tfh2 subset as an 289 interesting observation that warrants further studies. 290 291 Our data reveals an important association between Gag p24-specific nnAbs and viral load set 292 point. The exact mechanism of how nnAbs influence HIV replication requires further 293 investigation. Nevertheless, we speculate that the negative correlation between antibody titers 294 and lower viral load set point may be attributable to antibody effector functions that have been 295 14 associated with improved virus control (40) and slower HIV disease progression (41, 42) . 296
Although Fc effector functions like antibody-dependent cellular cytotoxicity (ADCC) and 297 antibody-dependent cellular phagocytosis (ADCP) have been described as important for virus 298 control, most of these functions were mostly attributed to 42) . 299
Studies investigating the mechanisms for virus suppression by Gag-specific antibodies have 300 described the ability of these Gag-specific antibodies to opsonize antigens and recruit 301 conventional or plasmacytoid dendritic cells to phagocytose antibody-coated antigens (43) (44) (45) . 302
Additionally, these opsonophagocytic IgG responses were associated with lower plasma 46) , thus, highlighting this as the potential mechanism of virus control. 304
Nevertheless, investigations into these and other antibody effector mechanisms are underway for 305 this cohort. 306 307 Early studies investigating the kinetics and magnitude of anti-Gag and anti-Env IgG antibodies 308 observed that the decay of Gag-specific antibodies correlated with poorer disease outcomes and 309 argued that Gag-specific antibodies are a surrogate for CD4 T cell help to Gag-specific CD8 T 310 cells (47). CD8 T cells are important for virus control and robust IL-21 mediated Tfh help to 311 CD8 T cells improves CD8 T cell cytolytic activity (37), but we observed no correlations 312 between the frequencies of IFN-γ + CD8 T cells and lower set point viral loads among our study 313 participants. Additionally, a paper from our group now in press showed that the association 314 between Gag-p24 IgG and viral control was still maintained even after controlling for Gag-315 specific CD4 and CD8 T cell responses suggesting a CD8 T cell independent anti-viral 316 mechanism of these antibodies (48). 317 318 15 A notable limitation of the study is the small sample size due to difficulty in recruiting subjects 319 with untreated acute HIV-1 infection in the present era of mass ART induction in all HIV-1 320 infected patients. Nevertheless, despite the small sample size, we generated statistically 321 significant results that provide new insight into the role of cTfh cells and their impact on the 322 induction of antibody responses during primary HIV infection. Further studies to validate our 323 findings in other acute infection cohorts are warranted. 324
325
In conclusion, the present study has identified a circulating Tfh1 subset whose frequency during 326 acute HIV infection predicts the development of anti-p24 non-neutralizing antibodies. We also 327
show that higher p24 IgG titers contribute to the control of HIV replication and have a beneficial 328 effect on HIV disease progression. These results highlight the important role of HIV-specific 329 cTfh cells in the generation of robust anti-HIV antibody responses, which are desirable for an 330 HIV vaccine. Additionally, the identification of a cTfh subset that predicts the development of 331 highly functional antibody responses might be useful to vaccine trials/studies as a potential bio-332 marker to predict the development of robust antibody responses in vaccine responders or as a 333 potential cell subset that can be manipulated to enhance vaccine responses (49). 334 335
Materials and Methods 336
Study Participants 337
Study participants comprised of 16 acute and 5 chronic HIV-infected ART-naïve individuals 338 from HIV Pathogenesis Programme (HPP) Acute Infection cohort, Durban, South Africa. 339
Patients were chosen based on availability of acute infection samples. Acute infection 340 classification and disease staging in this cohort was previously described (23). Briefly, at 341 16 screening, patients had detectable HIV RNA but had not yet seroconverted, either by ELISA or 342
Western blotting. The date of infection for the study participants was estimated to be 14 days 343 prior to screening as previously described (50 HIV-specific cTfh responses were measured using HLA class II tetramers. The immunodominant 377
Gag C41 epitope (26) was interrogated using DRB1*11:01 and DRB1*13:01 tetramers produced 378 in the laboratory of Dr Søren Buus as previously described (53). The design and validation of 379 these tetramers by our group have also been described (26). Briefly, recombinant human 380 DRB1*11:01 or DRB1*13:01 HLA molecules were complexed with clade C HIV-1 Gag 41 381 peptide (YVDRFFKTLRAEQATQDV). For the assay, PBMCs were stained for 1 hour at 37 o C 382 with APC and PE conjugated HLA class II tetramer complexes, washed in 2% fetal calf serum 383 (FCS) in phosphate buffered saline (PBS) and then stained with these antibodies: LIVE/DEAD 384 Plasma HIV-1 specific antibodies were measured using a customized multivariate Luminex 392 assay as previously described (54). Carboxylated fluorescent polystyrene beads (Biorad, 393 Hercules, CA, USA) were coated with HIV-1 specific proteins including gp120 clade C of strain 394 ZA.1197MB, gp41 clade C of strain ZA.1197MB, C-terminal 6xHis tagged p24 subtype C and 395 p17 HXBc2 (Immune Technology, New York, NY, USA). Plasma samples were incubated with 396 antigen-coated beads in a 96 well plate and unbound antibodies were washed with 0.05% Tween-397 20 in PBS. HIV-1 specific IgG antibodies were detected with phycoerythrin (PE) mouse 398 IgG1-IgG4 secondary antibodies. 399 400
Statistical analysis 401
Statistical analyses were performed using GraphPad Prism 7.0 (GraphPad Software, La Jolla, 402 California, USA). Mann-Whitney U tests were used for the comparisons between any 2 groups. 403
Variation across multiple groups was assessed using Kruskal-Wallis H test or two-way ANOVA. 404
The correlation between two variables were done using Spearman's rank correlation. P values 405 were considered significant if less than 0.05. 406 407 19 II tetramer validation. We would also like to acknowledge the following funding sources; HHMI 411
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